How to Get Zepbound in South Dakota

Zepbound Prescribing Is Legal via Telehealth in South Dakota

South Dakota allows licensed healthcare providers to prescribe Zepbound through telehealth platforms, making access possible even in the state's most rural counties. The South Dakota Board of Medical and Osteopathic Examiners permits synchronous audio-video consultations for establishing a valid prescriber-patient relationship, which satisfies the requirement for a controlled medication prescription.

A telehealth visit for Zepbound typically lasts 15 to 30 minutes. During the appointment, the prescriber reviews your medical history, body mass index, weight-related conditions (such as type 2 diabetes, hypertension, or obstructive sleep apnea), and current medications. If you meet the FDA-labeled criteria of a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity, the provider can send a prescription electronically to a retail or compounding pharmacy in South Dakota or in another state that ships to SD addresses [1].

Providers must hold an active South Dakota medical license or a compact license recognized by the state. South Dakota participates in the Interstate Medical Licensure Compact, which streamlines credentialing for physicians across member states. This means you may see a provider physically located in another compact state who holds a valid SD license. Nurse practitioners in South Dakota have full practice authority after completing a transition-to-practice period, so NPs can independently prescribe Zepbound without physician oversight once that period is complete.

One important detail: the prescriber should confirm that your pharmacy can dispense tirzepatide. Not every South Dakota retail pharmacy stocks Zepbound consistently due to intermittent supply constraints from Eli Lilly.

What Labs Do You Need Before Starting Zepbound in South Dakota?

Most prescribers require baseline labs before writing a Zepbound prescription. A standard pre-treatment panel includes fasting glucose or HbA1c, a lipid panel, a comprehensive metabolic panel covering liver and kidney function, and thyroid-stimulating hormone (TSH). These tests help rule out contraindications and establish a metabolic baseline.

The FDA prescribing information for tirzepatide carries a boxed warning about thyroid C-cell tumors observed in rodent studies. Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use Zepbound [2]. A baseline TSH helps screen for underlying thyroid dysfunction, though it does not detect MTC specifically. Calcitonin testing is not required by the label but may be ordered at clinician discretion.

South Dakota telehealth providers often partner with national lab networks (Quest Diagnostics, Labcorp, or local hospital outreach labs) so patients can complete bloodwork at a draw site near their home. Results are usually available within 48 to 72 hours. Some providers accept recent labs completed within the prior 90 days, so if your primary care physician already ran a metabolic panel, ask the telehealth provider whether those results will suffice.

A follow-up lab panel is typically ordered at 3 months and then every 6 to 12 months while on treatment. Monitoring HbA1c is especially relevant for patients with prediabetes or type 2 diabetes, since tirzepatide produces significant glycemic improvement. In the SURMOUNT-2 trial (N=938), participants with type 2 diabetes on the 15 mg dose achieved a mean HbA1c reduction of 2.1 percentage points at 72 weeks [3].

Clinical Evidence Behind Zepbound's Efficacy

Tirzepatide is a dual GIP/GLP-1 receptor agonist. That dual mechanism distinguishes it from semaglutide, which targets only the GLP-1 receptor. The SURMOUNT program is the key trial series that led to Zepbound's FDA approval for chronic weight management in November 2023.

In SURMOUNT-1 (N=2,539), adults without type 2 diabetes who received tirzepatide 15 mg weekly lost a mean of 22.5% of their body weight at 72 weeks, compared to 3.1% in the placebo group [1]. The 10 mg arm lost 21.4%, and the 5 mg arm lost 16.0%. These are the largest placebo-adjusted weight reductions reported for any anti-obesity medication in a phase 3 trial to date.

The American Association of Clinical Endocrinology (AACE) 2023 obesity treatment algorithm now includes tirzepatide as a first-line pharmacotherapy option for patients who meet BMI thresholds, alongside semaglutide 2.4 mg [4]. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity similarly recommends GLP-1 or dual GIP/GLP-1 agonists as preferred agents when lifestyle intervention alone produces insufficient weight loss [5].

Dr. Angela Chen, an endocrinologist on the HealthRX medical advisory board, notes: "The dual-agonist approach with tirzepatide appears to engage appetite and metabolic pathways that single-target GLP-1 drugs don't fully address. Clinically, we see patients reaching weight-loss thresholds that were previously only achievable with bariatric surgery."

Beyond weight, SURMOUNT-1 showed meaningful improvements in cardiometabolic markers. Systolic blood pressure dropped by 7.2 mmHg in the 15 mg group. Triglycerides fell by 24.8%. Fasting insulin decreased by 54.5% [1]. These secondary endpoints matter because the patients most likely to seek Zepbound in South Dakota carry the same cluster of metabolic risk factors.

Insurance Coverage and Cost in South Dakota

South Dakota Medicaid does not cover Zepbound for chronic weight management. This exclusion applies to both fee-for-service Medicaid and managed care plans administered within the state. The gap is consistent with most state Medicaid programs, which have been slow to add anti-obesity medications to their formularies despite FDA approval.

Commercial insurance coverage varies significantly by plan. Some large employers and national carriers (Blue Cross Blue Shield, UnitedHealthcare, Aetna, Cigna) have added tirzepatide to their formularies, though most require prior authorization. Eli Lilly's list price for Zepbound is approximately $1,059.87 per month for all dose strengths. The Zepbound Savings Card, available to commercially insured patients, can reduce the out-of-pocket cost to as low as $25 per month for eligible individuals [6].

For patients without insurance coverage, 503A compounding pharmacies offer compounded tirzepatide at lower price points. These pharmacies operate under state pharmacy board oversight and are permitted to compound patient-specific prescriptions. Compounded tirzepatide is not FDA-approved under the Zepbound brand name, but it contains the same active pharmaceutical ingredient prepared according to an individual prescription.

South Dakota's Board of Pharmacy licenses 503A compounding pharmacies and recognizes out-of-state 503A pharmacies that meet equivalent standards. Patients can receive compounded tirzepatide shipped to their South Dakota address from a licensed 503A facility in another state, provided the pharmacy holds any required non-resident pharmacy license with the SD Board of Pharmacy [7].

Pricing for compounded tirzepatide typically ranges from $300 to $550 per month depending on the dose, the pharmacy, and whether the prescription includes bacteriostatic water and syringes. Always verify that any compounding pharmacy you use is licensed and operates under Section 503A of the Federal Food, Drug, and Cosmetic Act. The FDA has issued warning letters to several compounders that failed current good compounding practices.

Who Can Prescribe Zepbound in South Dakota?

Three categories of licensed prescribers can write a Zepbound prescription in South Dakota: physicians (MDs and DOs), nurse practitioners (NPs), and physician assistants (PAs).

South Dakota granted full practice authority to nurse practitioners in 2017. After completing a collaborative agreement period of at least 720 hours with a supervising physician, NPs in the state can prescribe independently, including Schedule II through V controlled substances and non-controlled prescription drugs like tirzepatide. PAs in South Dakota prescribe under a collaborative agreement with a supervising physician and can prescribe Zepbound within the scope of that agreement.

For telehealth prescriptions specifically, the prescriber must be licensed in South Dakota or hold an active Interstate Medical Licensure Compact license covering the state. The South Dakota Board of Medical and Osteopathic Examiners maintains a license verification tool where patients can confirm a provider's credentials before scheduling a visit.

Obesity medicine specialists and endocrinologists may offer more tailored dosing protocols and metabolic monitoring, but board certification in obesity medicine is not required to prescribe Zepbound. Any licensed prescriber comfortable managing anti-obesity pharmacotherapy can initiate and titrate the medication.

The Zepbound Dose Titration Schedule

Zepbound uses a structured dose escalation to reduce gastrointestinal side effects. The starting dose is 2.5 mg once weekly for 4 weeks. This dose is for tolerability, not efficacy. After 4 weeks, the dose increases to 5 mg weekly. From there, the prescriber can increase in 2.5 mg increments every 4 weeks based on tolerability and clinical response, up to a maximum of 15 mg weekly [2].

Many patients reach their target weight-loss velocity at 10 mg and do not need to escalate to 15 mg. In SURMOUNT-1, the 10 mg group achieved 21.4% mean weight loss at 72 weeks, only 1.1 percentage points less than the 15 mg group [1]. The decision to escalate beyond 10 mg should balance additional efficacy against the potential for increased nausea, which was the most common adverse event across all dose groups.

The most frequently reported side effects in the SURMOUNT trials were nausea (24.6% at 15 mg vs. 9.5% placebo), diarrhea (18.7% vs. 7.3%), and constipation (11.7% vs. 5.8%) [1]. Most GI symptoms were mild to moderate and occurred during the dose-escalation phase. Slower titration or temporary dose reduction typically resolves persistent nausea.

South Dakota patients receiving Zepbound through telehealth should expect check-in visits at each dose escalation, either via video or asynchronous messaging depending on the platform. These visits allow the prescriber to assess tolerability, adjust the titration pace, and monitor for less common adverse effects such as acute pancreatitis or gallbladder events.

Prior Authorization Requirements for South Dakota Insurers

Most commercial plans that cover Zepbound require prior authorization (PA). The documentation typically needed includes:

A confirmed diagnosis of obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. The PA form generally requires chart documentation showing a minimum of 3 to 6 months of failed lifestyle intervention (diet, exercise, behavioral counseling). Some plans also require documentation of a failed trial with a first-line anti-obesity medication such as phentermine or orlistat before approving tirzepatide.

Lab values (fasting glucose or HbA1c, lipid panel, liver enzymes) are usually required to confirm the presence of comorbidities. A recent BMI measurement calculated from height and weight taken at a clinical visit (in-person or telehealth) is standard.

Turnaround time for PA decisions in South Dakota follows state insurance regulations and the applicable federal timeline for ERISA plans. Standard PA decisions must be returned within 15 calendar days. Urgent requests, which apply when a delay could seriously jeopardize life or health, require a response within 72 hours. If the initial PA is denied, patients have the right to an internal appeal followed by an external review through the South Dakota Division of Insurance.

Your prescribing provider's office or the telehealth platform typically handles the PA submission. Ask during your initial visit whether the practice has a dedicated PA team and what their approval rate is for GLP-1/GIP agonists.

How Long Until You Receive Zepbound After Your South Dakota Visit?

The timeline from first appointment to first injection depends on the prescribing pathway. For patients paying cash or using a compounding pharmacy, the process is fastest. A telehealth consultation can happen within 1 to 3 days of scheduling. If labs are already on file, the provider can send the prescription the same day. Compounding pharmacies typically ship within 3 to 5 business days, and standard shipping to South Dakota addresses takes 2 to 3 days. Total time: roughly 5 to 10 days from booking the visit.

For patients using commercial insurance, the prior authorization step adds time. PA submission to determination takes up to 15 days for standard requests. If approved, the specialty pharmacy fills and ships the brand-name Zepbound within 1 to 5 business days. Total time with insurance: 2 to 4 weeks from the initial visit, assuming approval on the first attempt.

Patients in Sioux Falls, Rapid City, and Aberdeen have the most local pharmacy options for same-day or next-day pickup if the medication is in stock. Rural patients elsewhere in South Dakota may find shipping more practical.

Transferring a Zepbound Prescription to South Dakota

If you hold an active Zepbound prescription from another state and are relocating to South Dakota, the transfer process depends on your pharmacy setup. Retail pharmacies can transfer prescriptions across state lines as long as the receiving pharmacy in South Dakota contacts the originating pharmacy and both pharmacies are licensed in their respective states. The prescriber's DEA registration and state license must be valid, though tirzepatide is not a controlled substance, which simplifies the process.

For compounding prescriptions, a direct transfer may not be possible because compounded prescriptions are patient-specific and pharmacy-specific. You will likely need your new prescriber (or your existing telehealth prescriber, if licensed in SD) to write a new prescription directed to your preferred compounding pharmacy.

Patients using telehealth platforms that operate in multiple states may not need a formal transfer at all. If the platform's prescriber is licensed in both your previous state and South Dakota, the prescriber can simply update the shipping address on file.